379 related articles for article (PubMed ID: 10520975)
1. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone.
Elliott AJ; Russo J; Bergam K; Claypoole K; Uldall KK; Roy-Byrne PP
J Clin Psychiatry; 1999 Apr; 60(4):226-31. PubMed ID: 10221282
[TBL] [Abstract][Full Text] [Related]
8. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.
Walczak DD; Apter JT; Halikas JA; Borison RL; Carman JS; Post GL; Patrick R; Cohn JB; Cunningham LA; Rittberg B; Preskorn SH; Kang JS; Wilcox CS
Ann Clin Psychiatry; 1996 Sep; 8(3):139-51. PubMed ID: 8899132
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine.
Kasper S; Möller HJ; Montgomery SA; Zondag E
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():3-12. PubMed ID: 7622821
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
Mehtonen OP; Søgaard J; Roponen P; Behnke K
J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656
[TBL] [Abstract][Full Text] [Related]
13. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.
Ravindran AV; Guelfi JD; Lane RM; Cassano GB
J Clin Psychiatry; 2000 Nov; 61(11):821-7. PubMed ID: 11105734
[TBL] [Abstract][Full Text] [Related]
14. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
[TBL] [Abstract][Full Text] [Related]
16. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
[TBL] [Abstract][Full Text] [Related]
17. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
Fontaine R; Ontiveros A; Elie R; Kensler TT; Roberts DL; Kaplita S; Ecker JA; Faludi G
J Clin Psychiatry; 1994 Jun; 55(6):234-41. PubMed ID: 8071277
[TBL] [Abstract][Full Text] [Related]
19. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
20. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Kiev A; Feiger A
J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
